Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

Autor: Guillaume Michel, Marwan Sahyoun, Laurent Castelnovo, Sarah Tick, Benjamin Wolff, Jeremie Halfon, Flore De Bats, Helene Masse, Maté Streho, Georges Azar, Vivien Vasseur, Martine Mauget-Faÿsse
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
medicine.medical_specialty
Article Subject
genetic structures
Visual Acuity
lcsh:Medicine
Spectral domain
Angiogenesis Inhibitors
Antibodies
Monoclonal
Humanized
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
0302 clinical medicine
Optical coherence tomography
Age related
Ophthalmology
Ranibizumab
medicine
Humans
030212 general & internal medicine
Aged
Retrospective Studies
Aged
80 and over
General Immunology and Microbiology
medicine.diagnostic_test
business.industry
lcsh:R
General Medicine
Diabetic retinopathy
Macular degeneration
medicine.disease
eye diseases
Treatment Outcome
Intravitreal Injections
030221 ophthalmology & optometry
Wet Macular Degeneration
Female
Treatment decision making
France
sense organs
business
Tomography
Optical Coherence
medicine.drug
Research Article
Zdroj: BioMed Research International, Vol 2018 (2018)
BioMed Research International
ISSN: 2314-6141
2314-6133
Popis: Purpose. To identify spectral-domain optical coherence tomography (SD-OCT) predictive morphological features for the outcome of Ranibizumab therapy for neovascular age-related macular degeneration (AMD). Methods. This is a retrospective multicentric study that involved 64 eyes with naïve AMD. Patients who received three monthly intravitreal injections of Ranibizumab were stratified into (1) “responders” [≥ 5 letters gain on Early Treatment Diabetic Retinopathy Study (ETDRS) scale] and (2) “nonresponders” (< 5 letters gain). Best-corrected visual acuity (BCVA) and SD-OCT morphological features were compared at baseline and one month after three consecutive injections of Ranibizumab. Univariate and multivariate analyses were carried out to correlate these morphological features with the change in BCVA. Results. Among the 64 patients enrolled, 40 (62.5%) were “responders” and 24 (37.5%) “nonresponders”. Age, sex, and BCVA were comparable between both groups. A multivariate correlational analysis found that subfoveal choroidal thickness (SFCT) and the presence of pigment epithelial detachment (PED) > 250 μm at baseline were two independent prognostic indicators of final BCVA. No other SD-OCT morphological studied features seem to affect final BCVA after Ranibizumab treatment. Conclusion. SFCT and the presence of PED > 250 μm are two significant biomarkers that may predict improvement after Ranibizumab therapy for AMD. These markers may guide ophthalmologists' treatment decision under financial constraints and limited time.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje